Mohsen Ebrahimi

Mohsen Ebrahimi

Auto-generated profile, based on publicly available information

Mohsen Ebrahimi

Iranian National Center for Addiction Studies (INCAS), Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
HEHamed Ekhtiari
Hamed Ekhtiari
MZMehran Zare-Bidoky
Mehran Zare-Bidoky
ASArshiya Sangchooli
Arshiya Sangchooli
AJAmy C. Janes
Amy C. Janes
MKMarc J. Kaufman
Marc J. Kaufman
AZAnna Zilverstand
Anna Zilverstand

29 April 2021 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PDF file
SRSeyed Ramin Radfar
Seyed Ramin Radfar
CJCornelis A. J. De Jong
Cornelis A. J. De Jong
AFAli Farhoudian
Ali Farhoudian
MEMohsen Ebrahimi
Mohsen Ebrahimi
PRParnian Rafei
Parnian Rafei
ICISAM-PPIG Global Survey Consortium
ISAM-PPIG Global Survey Consortium
Background:The coronavirus disease 2019 (COVID-19) pandemic has impacted people with substance use disorders (SUDs) worldwide, and healthcare systems have reorganized their services in response to the pandemic.Methods:One week after the announcement of the COVID-19 as a pandemic, in a global survey, 177 addiction medicine professionals described COVID-19-related health responses in their own 77 countries in terms of SUD treatment and harm reduction services. The health responses were categorized around (1) managerial measures and systems, (2) logistics, (3) service providers, and (4) vulnerable groups.Results:Respondents from over 88% of countries reported that core medical and psychiatric care for SUDs had continued; however, only 56% of countries reported having had any business continuity plan, and 37.5% of countries reported shortages of methadone or buprenorphine supplies. Participants of 41% of countries reported partial discontinuation of harm-reduction services such as needle and syringe programs and condom distribution. Fifty-seven percent of overdose prevention interventions and 81% of outreach services were also negatively impacted.Conclusions:Participants reported that SUD treatment and harm-reduction services had been significantly impacted globally early during the COVID-19 pandemic. Based on our findings, we highlight several issues and complications resulting from the pandemic concerning people with SUDs that should be tackled more efficiently during the future waves or similar pandemics. The issues and potential strategies comprise the following: (1) helping policymakers to generate business continuity plans, (2) maintaining the use of evidence-based interventions for people with SUDs, (3) being prepared for adequate medication supplies, (4) integrating harm reduction programs with other treatment modalities, and (5) having specific considerations for vulnerable groups such as immigrants and refugees.

4 February 2022 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
HEHamed Ekhtiari
Hamed Ekhtiari
PGPeyman Ghobadi-Azbari
Peyman Ghobadi-Azbari
ATAxel Thielscher
Axel Thielscher
AAAndrea Antal
Andrea Antal
LLLucia M. Li
Lucia M. Li
MBMarom Bikson
Marom Bikson

21 July 2020 in medRxiv
Verified
Preprint
Open access
PDF file
AFAli Farhoudian
Ali Farhoudian
SRSeyed Ramin Radfar
Seyed Ramin Radfar
HAHossein Mohaddes Ardabili
Hossein Mohaddes Ardabili
PRParnian Rafei
Parnian Rafei
MEMohsen Ebrahimi
Mohsen Ebrahimi
HEHamed Ekhtiari
Hamed Ekhtiari
Background and aims: COVID-19 has infected more than 13 million people worldwide and impacted the lives of many more, with a particularly devastating impact on vulnerable populations, including people with substance use disorders (SUDs). Quarantines, travel bans, regulatory changes, social distancing and ‘lockdown’ measures have affected drug and alcohol supply chains and subsequently their availability, price and use patterns, with possible downstream effects on presentations of SUDs and demand for treatment. Given the lack of multicentric epidemiologic studies, we conducted a rapid global survey within the International Society of Addiction Medicine (ISAM) network in order to understand the status of substance-use patterns during the current pandemic. Design: Cross-sectional survey. Setting: Worldwide. Participants: Starting on April 4 th , 2020 during a 5-week period, the survey received 185 responses from 77 countries. Measurements: To assess addiction medicine professionals’ perceived changes in drug and alcohol supply, price, use pattern and related complications during the COVID-19 pandemic. Findings: Participants reported (among who answered “decreased” or “increased”, percentage of those who were in majority is reported in the parenthesis) a decrease in drug supply (69.0%), and at the same time an increase in price (95.3%) globally. With respect to changes in use patterns, an increase in alcohol (71.7%), cannabis (63.0%), prescription opioids (70.9%), and sedative/hypnotics (84.6%) use was reported while the use of amphetamines (59.7%), cocaine (67.5%), and opiates (58.2%) was reported to decrease overall. Conclusions: The global report on changes in the availability, use patterns and complications of alcohol and drugs during the COVID-19 pandemic should be considered in making new policies and in developing mitigating measures and guidelines during the current pandemic (and probable future ones) in order to minimize risks to SUDs. Competing interest: Authors claimed no competing interest

29 April 2025 in Addiction
Verified
Journal Article
Open access
MTMatin Toulami
Matin Toulami
KGKeyvan Ghasemi
Keyvan Ghasemi
PRParnian Rafei
Parnian Rafei
ASArshiya Sangchooli
Arshiya Sangchooli
NNNastaran Nafissi
Nastaran Nafissi
HEHamed Ekhtiari
Hamed Ekhtiari
Background and Aims: The subjective experience of drug craving is characterized by an overwhelming urge to consume substances. Due to strong validity and ease of use, self‐report measures are widely employed to assess substance‐related motivational dynamics. Multi‐item questionnaires are increasingly favored for capturing the multidimensional nature of craving, providing valuable insights for clinical care and relapse prediction. This review aimed to summarize craving self‐report measurement tools registered in clinical trials and examine their methodological parameters.Methods: A search was conducted in November 2022 and updated in November 2024 using the same methodology on ClinicalTrials.gov for trials reporting drug craving as an outcome measure. Trials using craving measurement tools were screened and included.Results: From 5383 initial trials, 1255 met eligibility criteria. Craving was reported as the only primary outcome measure in 14.6%, one of the primary outcomes in 21.3% and as secondary or exploratory in 64.1% of the studies. The most studied substances were nicotine (32.5% of studies) and alcohol (27.5%), followed by opioids (14.2%). Multi‐item questionnaires were the most frequently used approach (55.4%), followed by single‐item questionnaires (27.3%) to measure craving. Among 107 identified multi‐item questionnaires, only 38 were used three or more times. The most common multi‐item questionnaires were the Questionnaire on Smoking Urges (20%), Penn Alcohol Craving Scale (12.1%) and Alcohol Urge Questionnaire (9.8%). Most trials focused on evaluating phasic (now) craving (51.6%) over tonic (in a certain time‐interval) craving (38%).Conclusion: Craving, measured through self‐reports, is increasingly targeted as a primary outcome measure in drug addiction trials registered on ClinicalTrials.gov. Craving self‐reports are highly variable, underscoring the need for standardized tools to enhance comparability across studies.

20 October 2020 in medRxiv
Verified
Preprint
Open access
PDF file
HEHamed Ekhtiari
Hamed Ekhtiari
MZMehran Zare-Bidoky
Mehran Zare-Bidoky
ASArshiya Sangchooli
Arshiya Sangchooli
AJAmy C. Janes
Amy C. Janes
MKMarc J. Kaufman
Marc J. Kaufman
AGAnneke Goudrian
Anneke Goudrian
Background: Cue reactivity is one of the most frequently used paradigms in functional magnetic resonance imaging (fMRI) studies of substance use disorders (SUDs). While there have been promising results elucidating the neurocognitive mechanisms of SUDs and SUD treatments, the interpretability and reproducibility of these studies is limited by incomplete reporting of participant characteristics, task design, craving assessment, scanning preparation and analysis decisions in fMRI drug cue reactivity (FDCR) experiments. This hampers clinical translation, not least because systematic review and meta-analysis of published work is difficult. This consensus paper and Delphi study aims to outline the important methodological aspects of FDCR research, present structured recommendations for more comprehensive methods reporting, and review the FDCR literature to assess the reporting of items that are deemed important.Methods: Fifty-five FDCR scientists from around the world participated in this study. First, an initial checklist of items deemed important in FDCR studies was developed by several members of the Enhanced NeuroImaging Genetics through Meta-Analyses (ENIGMA) Addiction working group based on a systematic review. Using a modified Delphi consensus method, all experts were asked to comment on, revise or add items to the initial checklist, and then to rate the importance of each item in subsequent rounds. The reporting status of items in the final checklist was investigated in 108 recently published FDCR studies identified through a systematic review.Results: By the final round, 38 items reached the consensus threshold and were classified under 7 major categories: “Participant Characteristics”, “General fMRI Information”, “General Task Information”, “Cue Information”, “Craving Assessment Inside Scanner”, “Craving Assessment Outside Scanner” and “Pre- and Post- Scanning Considerations”. The review of the 108 FDCR papers revealed significant gaps in the reporting of the items considered important by the experts. For instance, while items in the “general fMRI reporting” category were reported in 90.5% of the reviewed papers, items in the “pre- and post-scanning considerations” category were reported by only 44.7% of reviewed FDCR studies.Conclusion: Considering the notable and sometimes unexpected gaps in the reporting of items deemed to be important by experts in any FDCR study, the protocols could benefit from the adoption of reporting standards. This checklist, a living document to be updated as the field and its methods advance, can help improve experimental design, reporting, and the widespread understanding of the FDCR protocols. This checklist can also provide a sample for developing consensus statements for protocols in other areas of task-based fMRI.